Amidst the relentless pursuit to combat obesity, a recent study has emerged, shedding light on pills that could offer a convenient solution to address this epidemic. By introducing an oral alternative to the currently available injections, this development may provide millions of individuals with a more accessible means of managing their weight.
Novo Nordisk—the  Danish pharmaceutical company that manufacturers the type 2 diabetes medication Ozempic, which has gained fame as a celebrity weight loss sensation—announced that the company has developed an oral version that demonstrates comparable effects in reducing body weight.
Similarly, Pfizer has also been actively researching oral obesity drugs. A study published in JAMA Network revealed that danuglipron, an oral medication taken twice daily, has shown significant weight reduction in participants with type 2 diabetes….